share_log

Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $11

Benzinga ·  Oct 16, 2023 13:18

Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $14 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment